ICON plc | Clinical Research Organisation (CRO) for Drug Development

The Role of ICER as an Independent HTA Organisation

Primary research evaluating ICER’s influence over payers and manufactures

MDR/IVDR Brings Higher Costs and Bottlenecks

Develop the right business strategy to successfully navigate MDR/IVDR

The Impact of AI on Outcomes Based Contracting

Understanding formulary decision maker & manufacturer challenges

Key Considerations in Chronic Pain Clinical Trials

Determine the right design, assessments and endpoints in your pain study

ICON Insights

19 September 2019

Can AI improve R&D productivity enough to restore ROI to sustainable levels? Only if we carefully manage its deployment

According to an ICON survey, artificial intelligence (AI) was considered the digital technology with the most potential to improve R&D productivity

16 September 2019

Key Considerations for Disease-Modifying Parkinson’s Disease Trials

Taking into consideration the lessons learned from Alzheimer’s disease studies could benefit the design of neuro-protective studies.

09 September 2019

The importance of the patient voice in the rare disease market

Orphan drugs, by nature, remain commercially underdeveloped, and as demand in the market increases, patients in clinical trials need to be considered.

09 September 2019

Adoptive Cellular Transfer (ACT): Novel Cancer Trials Demand That Participating Sites Act Differently

Sites participating in ACT trials need to be prepared with regulatory intelligence, scalable logistics, adequate resources and dedicated data management teams.

09 September 2019

Alzheimer’s in Clinical Trials

Attempting to develop casual treatment against the progression of Alzheimer’s disease has resulted in unparalleled series of failures for nearly 2 decades of drug development.

09 September 2019

Oncology Clinical Trials in Asia Pacific

The size and significance of the APAC market make clinical trials, on the cutting edge of oncology development, an attractive investment.

29 August 2019

Generating RWE to maximise revenue in biotech trials

As more RWE is generated within the biotech industry, a strategic plan is necessary to maximise revenue.

12 August 2019

Alexa… What’s the deal with voice assistants?

As the buzz around voice technology increases, our digital team is asked more & more, “What’s the deal with voice assistants? Can we offer this to our clients?”

29 July 2019

The Long Journey towards Patient Centricity

Various regulatory efforts have been implemented in the last 25-30 years to include the patients’ perspective into drug development.

Services

Therapeutics

Innovation

Insights

News & Events

About ICON

How digital technologies will transform R&D productivity

Increasing complexity and declining ROI in drug development

Flow Cytometry for Driving Trials Forward

Site & Patient Solutions